Plain-English translation of NCT06630416 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a chemotherapy drug called in patients with advanced bladder cancer or other solid tumors that have stopped responding to previous treatments. The researchers believe this medication may work better in tumors with certain genetic mutations — specifically changes in genes called KMT2D, KDM6A, or MTAP. They want to see how many patients improve with this treatment and how long that improvement lasts.
Many patients with advanced bladder cancer and other solid tumors run out of treatment options after their cancer stops responding to standard chemotherapy. This trial exists because early evidence suggests this medication might be more effective in tumors with specific genetic changes, offering a new option for patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive the chemotherapy medication as an intravenous infusion (into your vein) for about 10 minutes on the first day of each 21-day cycle. Between treatments, you will have blood and urine samples collected and periodic CT scans to see if your tumor is shrinking. You will continue treatment cycles as long as your cancer isn't growing and you're tolerating the medication well. After your treatment ends, you will return for follow-up visits every 3 months for up to one year.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States